Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

Executive Summary

• Rakovina Therapeutics and Variational AI have signed a new agreement to expand their collaboration on the kt‑5000 series of ATR inhibitors, focusing on AI‑driven lead optimization.
• Variational AI will use its Enki™ generative AI platform to iteratively design and prioritize optimized compounds, aiming to identify a clinical candidate within months rather than years.
• The expanded partnership is intended to accelerate discovery, improve potency, selectivity, and CNS penetration of ATR inhibitors, potentially advancing candidates toward human trials faster.

Key Details

• Scope of Expansion: New agreement adds lead‑optimization work for drug candidates identified by Variational AI’s Enki™ platform and selected by Rakovina for the kt‑5000 ATR inhibitor program.
• Objective: Reduce early‑stage discovery timelines from years to months while lowering cost; generate multiple optimized compound designs for Rakovina’s evaluation.
• Roles & Responsibilities:
• Variational AI – Generates, prioritizes, and iteratively refines chemical structures using Enki™; conducts local chemical search to explore novel space.
• Rakovina – Retains full decision‑making authority on which AI‑generated candidates advance to laboratory testing and further development.
• Therapeutic Focus: ATR inhibition targeting DNA‑damage response in solid tumors (e.g., ovarian, breast, prostate) with an emphasis on CNS penetration and dual ATR/mTOR activity.
• Recent Preclinical Results: Rakovina presented kt‑5000 series data—including dual ATR/mTOR compounds with CNS penetration—at the Society for NeuroOncology annual meeting.
• Strategic Rationale (Quotes):
• Jeffrey Bacha, Executive Chairman, Rakovina: Emphasized that AI‑driven refinement will enhance potency, selectivity, and CNS penetration while preserving strategic flexibility.
• Handol Kim, Co‑Founder & CEO, Variational AI: Highlighted Enki™’s ability to explore novel chemical space efficiently and accelerate progression to human trials.

Notable Quotes

• “ATR is a proven oncology target, but real differentiation comes from optimizing the drug itself… The result is a more efficient path to identifying high‑quality candidates while maintaining strategic flexibility for development and partnering.” – Jeffrey Bacha, Executive Chairman, Rakovina Therapeutics
• “Our Enki™ generative AI platform efficiently explores novel chemical space and has already generated promising leads for Rakovina… enabling Rakovina to get to human trials faster.” – Handol Kim, Co‑Founder & CEO, Variational AI

Materiality Assessment

• Material - Positive – The expanded collaboration represents a significant strategic development that could materially impact Rakovina’s pipeline timeline and valuation.